

Research Article

ptk2 and *mt2a* Genes Expression in Gastritis and Gastric Cancer Patients with *Helicobacter pylori* Infection

Manouchehr Ahmadi Hedayati ^{1,2}, Delniya Khani ², Farshad Sheikhesmaeili ¹,
and Bijan Nouri ³

¹Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran

²Department of Microbiology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran

³Department of Epidemiology and Biostatistics, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran

Correspondence should be addressed to Manouchehr Ahmadi Hedayati; dr.ahmadi2000@gmail.com

Received 16 June 2022; Revised 15 July 2022; Accepted 27 July 2022; Published 25 August 2022

Academic Editor: Alessandro Granito

Copyright © 2022 Manouchehr Ahmadi Hedayati et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. *ptk2* and *mt2a* genes contribute to the cell cycle during proliferation and apoptosis, respectively. Designing a case-control study including gastric adenocarcinoma and gastritis patients with and without *Helicobacter pylori* infection would lead to determinate of the correlations between *ptk2* and *mt2a* genes expression with *H. pylori* infection in gastric antral epithelial cells. **Methods.** Overall, 50 and 30 gastric antral biopsy samples of gastric cancer (case group) and gastritis (control group) patients were included into study, respectively. All biopsy samples were collected considering the exclusion criteria including patients with a history of consumption of tobacco, alcohol, and anti-*H. pylori* drugs. Each patient group is divided into with and without *H. pylori* infection to detect cDNA fold changes of *ptk2* and *mt2a* genes by using Real Time RT PCR. Furthermore, the presence of *H. pylori* virulence genes was detected directly by using specific primers and simple PCR on cDNA synthesized from total RNA of gastric antral biopsy samples. **Results.** A negative correlation was revealed between age and clinical manifestations with the Δ Ct value of the *ptk2* gene ($P < 0.05$). The *H. pylori iceA1/2* and *cagE* genes revealed positive and negative correlations with the Δ Ct value of the *ptk2* gene ($P < 0.05$), respectively. Furthermore, a weak correlation was detectable between *H. pylori babA2/B*, *oipA*, and *cagY* genes and the Δ Ct value of the *mt2a* gene in gastric antral epithelial cells of patients ($P < 0.1$). **Conclusions.** The results of the current study opened a view for more investigation on the stunning roles of *H. pylori* infection in clinical outcomes through *mt2a* and *ptk2* gene expression in gastric antral epithelial cells.

1. Introduction

In a close competition between carcinogenic agents and natural anti-cancer drugs such as *Allium*, cell signaling molecules are considered the effective targets [1]. In this regard, it has been revealed that the main pathways of natural anticancer drugs are to induce apoptosis by activating the MAPK and PI3K/AKT signaling pathways suppressing tumor growth [1]. In this meantime, Mt2a (Metallothionein 2A) as a member of the metallothionein proteins family contributes to critical roles including increasing intracellular concentration of heavy metals,

protecting the cells against the toxicity of hydroxyl free radicals and heavy metals affecting cell apoptosis, proliferation, angiogenesis, and anti-inflammatory processes [2–4]. As a critical role in cell cycling, Metallothioneins control HMBOX1 (Homeobox containing 1) protein bound to the double-stranded repeat sequence of telomeres following regulation of zinc intracellular concentration [5–8]. Recent studies have shown that following LPS-induced inflammation and ROS production, HMBOX1 inhibits NF- κ B and the MAPK signaling pathway [1, 9]. In this regard, MT2A protein exerts its anti-cancer effects through inactivation of NFKBIA (NFKB Inhibitor Alpha) subsequent binding to

MZF1 (Myeloid Zinc Finger 1) [9, 10]. As a clinical impact of MT2a, it has recently been shown that attenuation of MT2A and I κ B- α gene expression in human gastric epithelial cells is associated with a poor prognosis in gastric cancer patients [9, 10]. Furthermore, some *mt2a* gene polymorphisms, including rs28366003 and rs1610216, are associated with an increased risk of cancer [11–13]. In this regard, some MT-2A gene polymorphisms are associated with adenocarcinoma risk in the Iranian patient population [14]. Moreover, in the Polish population, the rs28366003 SNP polymorphism has been associated with breast and prostate cancer [15].

On the other hand, the *ptk2* gene encodes a cytoplasmic tyrosine kinase protein, namely, FAK (Focal Adhesion Kinase) [16–18]. The FAK/Paxillin signaling pathway conducts a substantial effect on the cell migration following activating SH2 domains of the Src kinase family and consequentially triggering downstream-activating signals leading to the regulation of cell motility, invasion, survival, and proliferation [19]. The changes in *ptk2* gene expression are associated with the pathological stage, progression, and cancer's specific survival [20]. There is evidence to support the role of FAK in promoting malignant phenotypes (unregulated cell proliferation, survival, and migration) of various tumor cells in vitro [21, 22]. The *ptk2* gene over-expression is commonly seen in metastatic cancers and is obviously associated with malignant clinical outcomes [23–25]. Furthermore, inhibitors of FAK kinase exert suppressing cancer cell growth in clinical trials [26–28]. In the other studies, the *ptk2* gene over-expression is well-known as a pathological risk factor predicting aggressive biological behavior of bladder carcinoma cells [29]. Considering a previous study, FAK is highly expressed in human gastric cancer cells and correlated with tumor progression, invasion, and metastasis [30]. To conclude, the studies show that the Fak protein and its gene [*ptk2*] are significantly associated with cancer progression [31, 32].

H. pylori as the most common causative agent of chronic infections in humans shows a full long history related to clinical implications from gastritis to gastric cancer [33]. In this regard, the studies show that the *H. pylori* virulence factors have an indispensable impact on the clinical consequences of *H. pylori* persistent active infection [33–37]. In the meantime, the epidemiological studies show that *H. pylori* adhesins, including Sab, Bab, and the type 4 secretory system (T4SS), are related to peptic ulcers and gastric cancer [33–36]. CagA suppresses the apoptotic activity of VacA and activates the signaling pathway of the factor NF- κ B inducing overexpression of anti-apoptotic agents [33]. On the other hand, CagY and CagL proteins, as the significant members of T4SS proteins with a tubular structure, following contact with gastric epithelial cell surface receptors, including beta-1 integrin receptors, inject CagA carcinogen protein into the gastric epithelial cell [37–40]. Therefore, it is worth to mention that despite the presence of the *cagA* gene in the *H. pylori* strains genome, due to possible changes in the *cagY* gene expression under the full stress environment of the stomach, the CagA protein could not be able to inject into host cells [39]. This study investigated the correlation

between the *H. pylori* virulence genes and *ptk2* and *mt2a* genes expression in gastric antral epithelial cells of gastritis and gastric cancer patients with *H. pylori* infection.

2. Materials and Methods

2.1. Sampling. A case-control study was designed on patients who had involved gastric adenocarcinoma and gastritis [41, 42]. Considering the prevalence of gastric adenocarcinoma and *H. pylori* infection in Sanandaj city, located in the west of Iran, using Cochran's formula, 30 and 50 patients with gastric adenocarcinoma and gastritis were registered [42]. Patients with a history of anti-*H. pylori* chemotherapy, alcohol, and cigarette consumption were excluded from the study. According to the study's aim, to investigate *H. pylori* infection's effect on the *mt2a* and *ptk2* genes expression, the gastric biopsy samples were collected from patients referred to Tohid Hospital in Sanandaj city. The *H. pylori* active infection was detected by using a urea breath test [43, 44]. Two gastric biopsy specimens were obtained from each patient by a gastroenterologist. One biopsy sample was prepared from the gastric antrum, the natural site of *H. pylori* infection, to detect *H. pylori* virulence genes and study *mt2a* and *ptk2* gene expression using PCR, and another biopsy from the gastric adenocarcinoma tumor area to pathologic evaluation. The gastric antral biopsy sample for molecular analysis was immediately dropped into RNA Later solution and transferred to the Molecular Microbiology Laboratory of Kurdistan University of Medical Sciences. On the other hand, the gastric tumor area biopsy samples including cardia, body, or pyloric area, were evaluated at the pathology center of Tohid Hospital.

2.2. PCR. First of all, total RNA was extracted from gastric antral biopsy samples (Miniprep Kit; Bio Basic Company, Toronto, Canada) and immediately converted to cDNA (Prime Script TM RT-PCR Kit; Takara Company, Japan). To survey the presence of the *H. pylori* genome in gastric antral biopsy samples, *H. pylori* 16s rRNA gene-specific primer and PCR method were used. Primers of *H. pylori* virulence genes were designed by using primer3 online software and blast on the PubMed website and then were synthesized by Bioneer company (South Korea; Tables 1 and 2). The thermocycler program was set based on the current protocols. Using Takara kits (Emerald Amp[®] MAX PCR Master Mix), PCR master mix was prepared. Single PCR steps were performed according to the current PCR protocols and using annealing temperatures of primers in a final volume of 25 microliter (Eppendorf[®] Co.; Tables 1 and 2) (17). Based on agarose gel electrophoresis protocols, PCR products were run on 1% agarose gel to observe PCR results. To prove the *H. pylori* genome, the *H. pylori vacA m2* gene was sequenced and registered in the GenBank with accession number MK642592.1.

2.3. Real-Time RT PCR. To detect *mt2a* and *ptk2* genes' expression in the gastric biopsy samples by using the Real-Time RT PCR method (Corbett machine, Co.), the specific

TABLE 1: Primers of *H. pylori* T4SS, *16s rDNA*, and *vacA* in simple PCR.

Specific primers	Sequence	Annealing Tm°C	Product size bp	Reference
<i>16s rDNA H. pylori</i> F	CTGGAGAGACTAAGCCCTCC	50	446	This study
<i>16s rDNA H. pylori</i> R	AGGATCAAGGTTTAAGGATT			
<i>cagA</i> F	TGACCAACAACCACAAACCG	57	108	This study
<i>cagA</i> R	TCAGGATCGTATGAAGCGACAG			
<i>cagA</i> EPIYA-C F	AAGAAAGCAGGACAAGCAGC	55	188	This study
<i>cagA</i> EPIYA-C R	CTAACCGATCGCCCTACCTT			
<i>cagT</i> F	AGGGTGTGGTGATGATAGCG	55	154	This study
<i>cagT</i> R	TGCTTGTTGTTTGCTCCACT			
<i>cagE</i> F	GAATGGAGCGAGCGATGAAA	56	163	This study
<i>cagE</i> R	TAGGAATTTGCAGCGCTCAC			
<i>cagY</i> F	AGTTC AAGTGGCGCTAGATTG	57	200	This study
<i>cagY</i> R	ACAAGCCTTTCAAGCATTTCGT			
<i>vacA</i> s1/s2 F	ATGGAAATACAACAAACACAC	55	259/286*	Atherton et al. [46]
<i>vacA</i> s1/s2 R	CTGCTTGAATGCGCCAAAC			
<i>vacA</i> m1/m2 F	TGGATAGTGC GACTGGGTTT	54	205/220*	This study
<i>vacA</i> m1/m2 R	TCCATGCGGTTGTTGTTGTT			

*The primers yield various fragments of *vacA* depending on the presence of a repetitive nucleotides sequence in some *vacA* alleles.

TABLE 2: Primers of *H. pylori* adhesins and surface proteins.

Specific primers	Sequence	Annealing Tm°C	Product size bp	Reference
<i>iceA1</i> F	GTGTTTTTAACCAAAGTATC	45	247	Van Doorn et al. [47]
<i>iceA1</i> R	CTATAGCCASTYTCTTTGCA			
<i>iceA2</i> F	GTTGGGTATATCACAATTTAT	47	229/234	Van Doorn et al. [47]
<i>iceA2</i> R	TTRCCCTATTTTCTAGTAGGT			
<i>hopQI</i> F	ACGAACGCGCAAAAACCTTTA	55	187	Sicinschi et al. [48]
<i>hopQI</i> R	TTGCCATTCTCATCGGTGTA			
<i>hopQII</i> F	ACAGCCACTCCAATCCAGAA	55	160	Sicinschi et al. [48]
<i>hopQII</i> R	AACCCACCGTGGATTTTAG			
<i>babA2</i> F	CAATGCGGTGCGTGA AAAATC	57	205	This study
<i>babA2</i> R	ATACCCTGGCTCGTTGTTGA			
<i>babB</i> F	CAATCCCCGGCGTATCAAG	56	175	This study
<i>babB</i> R	ATTGCAAGTGATGGTCTGTCG			
<i>sabA</i> F	TCTCTCGCTTGCGGTATCAT	56	204	This study
<i>sabA</i> R	AGCTCAATGTTGTTGGCGTT			
<i>sabB</i> F	GCATTCAAACGGCGAACAAC	56	248	This study
<i>sabB</i> R	TCCTGTGCAGTCCCATCTT			
<i>alpA</i> F	CGCTCCTATCAAAAACCGCTC	55	185	This study
<i>alpA</i> R	TTCCCGTCCAACCTACCGAA			
<i>alpB</i> F	TCAACTTGCGAGCAGACCTA	57	218	This study
<i>alpB</i> R	AGCCATAGACCCCATACACG			
<i>oipA</i> F	CTCCACGCTGAAAGGAATGG	55	233	This study
<i>oipA</i> R	CCATTTCCCTGCGAATCGGTT			

TABLE 3: Specific Primers of *ptk2* and *mt2a* in Real-Time RT PCR.

Specific primers	Sequence	Annealing Tm°C	Product size bp	Reference
<i>GAPDH</i> F	GAAGGTGAAGGTCGGAGTCAAC	60	71	
<i>GAPDH</i> R	CAGAGTTAAAAGCAGCCCTGGT			
<i>ptk2</i> F	GCACCCACCGAGAGATTGAG	60	81	[49]
<i>ptk2</i> R	GGGCCAGTTTCATCTTGTGTA			
<i>mt2a</i> F	GCCCAGGGCTGCATCTG	60	102	[50]
<i>mt2a</i> R	TTTGTGGAAGTCGCGTCTTTA			

TABLE 4: Demographic data of patients.

	Gastritis	Gastric cancer	Total	P value
<i>H. pylori</i> infection (positive/negative)	23/27	11/19	34/46	0.487
Sex (male/female)	24/26	24/6	48/32	0.024
Age group (18–30/31–45/46–60/61–85)	10/18/17/5	0/0/7/23	10/18/24/28	0.005

TABLE 5: The frequency of *H. pylori* infection among males and females in various age groups.

<i>H. pylori</i> infection	Sex (n: 80)		Age group (n: 80)			
	Male	Female	18–30	31–45	46–60	61–85
<i>H. pylori</i> infection (positive, n: 34)	19	15	2	10	11	11
<i>H. pylori</i> infection (negative, n: 47)	29	17	8	8	13	17
Total	48	32	10	18	24	28

TABLE 6: Correlations between *ptk2* and *mt2a* Δ Ct and patients' demographic characters.

	Sex	Age group	Disease	<i>H. pylori</i> infection	Gastric cancer area	Tumor grade
<i>ptk2</i> correlation	0.080	-0.334	-0.379	0.042	-0.107	0.345
P value	0.589	0.002	0.001	0.779	0.636	0.116
<i>mt2a</i> correlation	0.146	-0.055	-0.104	-0.049	0.041	0.257
P value	0.323	0.710	0.482	0.742	0.858	0.248

primers of *mt2a* and *ptk2* as the target genes and GAPDH as the internal genes were designed by using primer3 software and their genes sequences in the GenBank (Table 3). Takara kits (Emerald Amp® MAX PCR Master Mix) were used to prepare the PCR master mix. The PCR amplification program included a 10 minutes denaturation step at 95°C and 40 cycles of denaturation at 95°C for 15 seconds, specific annealing temperatures for 30 seconds, and extension at 72°C for 60 seconds. The relative quantity of the *mt2a* and *ptk2* genes expression in gastritis (control group) and gastric adenocarcinoma (case group) patients were calculated by Δ Ct (threshold cycle) = Ct (DNMT1) Ct (GAPDH). The mean of Ct of each 3 PCR reactions was put on the Δ Ct formula to compute the fold change of each gene in the case and control groups by using the $2^{-\Delta\text{Ct}}$ formula [43–45].

2.4. Statistical Analyses. Quantitative and qualitative data analysis was performed using SPSS software version 26. Crosstab chi-square tests were used to survey the correlation and relationship between qualitative data [41, 42]. First, the quantitative data distribution status was determined using Kolmogorov–Smirnov statistical test [42]. The distribution of *mt2a* and *ptk2* genes Δ Ct was abnormal. Accordingly, Mann–Whitney and Kruskal–Wallis tests were used to investigate the correlation between quantitative data and comparison in the case and control groups and subgroups [42]. The significance level was considered less than 0.05 [41].

3. Results

Based on the urea breath test results, 46% and 36.66% of gastritis and gastric adenocarcinoma patients showed *H. pylori* active infection, respectively (Table 4). It revealed

that because of an anti-*H. pylori* drug without medical registration, the prevalence of *H. pylori* active infection among gastric adenocarcinoma patients was significantly lower than in gastritis patients (Table 4). Like in the previous studies, the frequency of *H. pylori* infection and gastric adenocarcinoma increased along with increasing age ($P < 0.001$; Tables 4 and 5).

Besides the genetic factors, exposure to environmental carcinogens factors, diet and *H. pylori* infection contribute to increasing gastric cancer risk [43, 44]. In this regard, although the results of the current study showed that the prevalence of gastric adenocarcinoma is significantly higher in men ($P < 0.05$; Table 4), it is worthy of note that this significant difference was not related to *H. pylori* infection (Table 5).

The changes of *ptk2* and *mt2a* genes Δ Ct in demographic subgroups indicated a negative correlation between *ptk2* gene Δ Ct with patients' age and clinical manifestations (Table 6 and Figure 1). This means that the *ptk2* gene expression in gastric antral epithelial cells increases with getting older and gastric cancer up 2.51 and 4.32 times, respectively ($P < 0.005$). In addition, a significant decrease of Δ Ct of the *ptk2* gene was revealed in patients with *H. pylori* *cagE*⁺ strains infection (Table 7). In these cases, *ptk2* gene expression increased 5.06-fold compared to *cagE*⁻ samples ($P < 0.05$; Table 8). On the other hand, gastric antral biopsies with infection of *H. pylori* *iceA1/2*⁺ strains showed a positive correlation with the Δ Ct of the *ptk2* gene ($P < 0.005$). In samples with *iceA1/2*⁺ cDNA, the expression level of the *ptk2* gene increased by 7.66-fold than in samples with *iceA2*⁺ cDNA ($P < 0.005$).

Although no correlation was observed between *H. pylori* infection and Δ Ct of *ptk2* and *mt2a* genes, a weak correlation was observed between *mt2a* gene Δ Ct and subgroups with *babA2/B*, *oipA*, and *cagY* cDNA ($P < 0.1$; Table 9). In




FIGURE 1: A simple scatter plot of ΔCt of the *ptk2* gene depicts a reverse relationship with R^2 linear 0.057. This means the *ptk2* gene expression will increase along with increasing age.

TABLE 7: Correlations between *ptk2* and *mt2a* ΔCt and gene expression of *H. pylori* virulence genes in gastric antral epithelial cells of gastritis and gastric adenocarcinoma patients.

	<i>vacA</i>	<i>s1m1/s1m2</i>	<i>cagA</i>	<i>cagA-EPEAYC</i>	<i>cagT</i>	<i>cagY</i>	<i>cagE</i>	<i>sabA/B</i>	<i>babA2/B</i>	<i>hopQI/II</i>	<i>alpA/B</i>	<i>oipA</i>	<i>iceA1/2</i>
<i>ptk2</i> correlation	0.320	-0.216	-0.156	-0.082	-0.238	-0.390	-0.215	0.192	-0.192	0.186	0.152	0.519	
<i>P</i> value	0.065	0.312	0.468	0.804	0.262	0.023	0.314	0.370	0.368	0.384	0.472	0.002	
<i>mt2a</i> correlation	-0.256	0.292	0.304	0.009	-0.378	0.289	-0.367	-0.388	0.040	-0.093	-0.348	-0.293	
<i>P</i> value	0.227	0.166	0.149	0.966	0.068	0.171	0.087	0.061	0.854	0.665	0.095	0.165	

TABLE 8: The statistical relationships of *ptk2* genes expression with *H. pylori* infection and its virulence genes expression using Mann-Whitney *U* test. Fold changes of *ptk2* gene expression were calculated by using the average of *ptk2* ΔCt in the case and control groups ($P < 0.05$).

		<i>N</i>	Mean rank	<i>Z</i>	<i>P</i> value	Mean ΔCt <i>ptk2</i>	Fold change
Disease	Adenocarcinoma	30	29.20	-3.371	0.001	5.4730	2.51
	Gastritis	50	47.28				
Age group	61-85	28	18.48	-3.163	0.002	5.6203	4.32
	31-45	18	31.31				
<i>iceA1/2</i>	<i>iceA2iceA1/2</i>	17	12.4122.59	-2.983	0.002	4.8719	7.66
		17					
<i>cagE</i>	Positive	5	8.3	-2.239	0.023	4.3460	5.06
	Negative	29	19.09				

TABLE 9: The statistical results of *mt2a* gene expression with *H. pylori* infection and its virulence genes expression using Mann-Whitney *U* test. Fold changes of *mt2a* gene expression were calculated by using the average of *mt2a* ΔCt in the case and control groups ($P < 0.01$).

		<i>N</i>	Mean rank	<i>Z</i>	<i>P</i> value	Mean ΔCt <i>mt2a</i>	Fold change
<i>babA2/B</i>	Negative	17 3	9.08	-1.876	0.061	5.3767	5.14
	<i>babA2/B</i>		3.67				
<i>oipA</i>	Negative	3 31	20.50	-1.671	0.095	6.1300	2.71
	Positive		11.77				
<i>cagY</i>	<i>CagY-MRR</i>	13 21	9.40	-1.815	0.068	4.1490	2.2
	negative		14.71				

samples with *babA2/B*⁺ cDNA, the expression of the *mt2a* gene increased 5.14-fold than in samples with *babA2/B*⁻ cDNA ($P < 0.005$; Table 9).

4. Discussion

MT2A, as an oxidative shock protein protecting cell DNA, influences the cell cycle through apoptosis [2–4]. Pan et al. showed that overexpression of the *mt2a* gene is associated with increasing tumor grade and poor gastric cancer prognosis [10]. They showed that MT2A induces apoptosis by stopping the G2/M phase of the cell cycle, and the effect of MT2A on apoptosis is due to the suppression of the NF- κ B signaling pathway [9, 10]. Wang et al. showed that MT2A increases the expression of P21 and BAX proteins by affecting P53 which is a pre-apoptotic protein triggering the cell death process [12].

Previous studies show the positive correlations between *mt2a* gene polymorphisms and breast, liver, and prostate cancers [11–15]. In a comparison, the results of the current study showed no statistically significant correlation between *mt2a* gene Δ Ct and patients' demographic characteristics, including clinical manifestations, tumor grade, adenocarcinoma tumor area, age, sex, and *H. pylori* infection (Table 5). On the other hand, weak and negative correlations were observed between the cDNA of *babA2/B*, *oipA*, and *cagY* virulence genes of *H. pylori* with *mt2a* gene Δ Ct ($P < 0.1$; Table 7). The *mt2a* gene expression in gastric biopsy samples with *H. pylori babA2/B*⁺ cDNA was higher up to 5.14-fold than in biopsy samples with *H. pylori babA2/B*⁻ cDNA (Table 9). These results indicate that the simultaneous expression of *H. pylori babA2*⁺ and *babB*⁺ genes (*babA2/B*⁺ cDNA) correlates weakly with increased *mt2a* gene expression ($P < 0.1$). Furthermore, previous studies have shown the negative and positive correlations between gastric cancer with *H. pylori babA2/B* and *cagE*, *cagA*, and *iceA1* genes expression, respectively (Table 9).

Aras et al. showed that the *cagY* gene has two reproducible and variable regions at the 5' end sequence including forward (FRR) and middle (MRR) [38]. They showed that following an increase or decrease in the copy number of reproducible sequences, the *cagY* gene expression and consequently CagY protein's efficiency to bind to β 1 integrin receptors of gastric epithelial cells will change [38]. They revealed that changes in the CagY protein antigens would give a trait to bacteria to escape from the gastric mucosal immune system and establish a persistent infection [38]. The present study showed a statistically weak correlation between the *H. pylori cagY* gene with the MRR region and increased *mt2a* gene expression up to 2.2 times ($P < 0.1$; Table 9). The *mt2a* gene expression in the biopsy specimens with the *H. pylori cagY-MRR*⁺ cDNA was higher than in the biopsy specimens with the *H. pylori cagY-MRR*⁻ cDNA ($P < 0.1$).

FAK protein is known as a tyrosine kinase integrin that its gene expression will increase along with cancer progression [19–22]. Some studies have shown a gradual increase in FAK protein (*ptk2* gene) related to poor cancer prognosis [29]. Zhang et al. showed a high *ptk2* gene

expression correlated with aggressive traits of bladder squamous cell carcinoma [29]. Their Kaplan–Meyer analysis also showed a correlation between *ptk2* gene expression and the pathological stages, invasion of the disease, and reduced chance of survival in carcinoma [29]. The present study showed that the *ptk2* gene expression and the frequency of gastric cancer increase along with increasing age ($P < 0.001$).

Previous studies, based on the bacterial effects on the host cytoskeleton, show Hijacking of the FAK/Paxillin pathway to control cell physiological trends [51]. In this regard, Kim et al. showed following being attached *Shigella flexneri* OspE protein to integrin-binding kinase, the integrin B1 gene expression will be increasing, and suppression occurs as a result of phosphorylation of FAK and Paxillin [51].

5. Conclusion

In a remarkable conclusion, this study showed that the gastric antral epithelial samples with infection of *H. pylori iceA1/2* and *cagE* genotypes reveal a strong correlation with increased *ptk2* gene expression ($P < 0.001$).

Data Availability

All data are already released in the article results and the raw datasets used and/or analyzed during the current study are not publicly available due to contracts with research participants but are available from the corresponding author upon reasonable request.

Consent

The institutional review board has approved the study as no published patients' names were involved in the research project.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors' Contributions

Manouchehr Ahmadi Hedayati, the corresponding author, investigated and designed the study, Primers and Real-Time PCR; Delniya Khani was responsible for sampling, Real-Time PCR; Farshad Sheikhesmaeili: was responsible for sampling; and Bijan Nouri was responsible for statistical analysis.

Acknowledgments

This study results from Manouchehr Ahmadi Hedayati's (Ph.D. of Medical Bacteriology) academic research. The authors thank Doctor Bahram Nikkhoo (Pathologist), Doctor Roghayeh Ghadyani [Internal Medicine], and Sanaz Ahmadi for supporting sampling. This study was supported and funded by the Kurdistan University of Medical Sciences by code number IR.MUK.REC.1397/212.

References

- [1] A. Forma, Z. Chilimoniuk, J. Januszewski, and R. Sitarz, "The potential application of allium extracts in the treatment of gastrointestinal cancers," *Gastroenterology Insights*, vol. 12, no. 2, pp. 136–146, 2021.
- [2] M. Vasak and G. Meloni, "Chemistry and biology of mammalian metallothioneins," *Journal of Biological Inorganic Chemistry*, vol. 16, no. 7, pp. 1067–1078, 2011.
- [3] X. B. Ling, H. W. Wei, J. Wang et al., "Mammalian metallothionein-2A and oxidative stress," *International Journal of Molecular Sciences*, vol. 17, p. 1483, 2016.
- [4] M. Yang and C. R. Chitambar, "Role of oxidative stress in the induction of metallothionein-2A and heme oxygenase-1 gene expression by the antineoplastic agent gallium nitrate in human lymphoma cells," *Free Radical Biology and Medicine*, vol. 45, no. 6, pp. 763–772, 2008.
- [5] N. Chiaverini and M. De Ley, "Protective effect of metallothionein on oxidative stress-induced DNA damage," *Free Radical Research*, vol. 44, no. 6, pp. 605–613, 2010.
- [6] H. Ma, L. Su, H. Yue et al., "HMBOX1 interacts with MT2A to regulate autophagy and apoptosis in vascular endothelial cells," *Scientific Reports*, vol. 5, Article ID 15121, 2015.
- [7] H. Ma, L. Su, X. He, and J. Miao, "Loss of HMBOX1 promotes LPS-induced apoptosis and inhibits LPS-induced autophagy of vascular endothelial cells in mouse," *Apoptosis*, vol. 24, no. 11–12, pp. 946–957, 2019.
- [8] H. X. Yuan, X. E. Feng, E. L. Liu et al., "5, 2'-dibromo-2, 4', 5'-trihydroxydiphenylmethanone attenuates LPS-induced inflammation and ROS production in EA.hy926 cells via HMBOX1 induction," *Journal of Cellular and Molecular Medicine*, vol. 23, no. 1, pp. 453–463, 2019.
- [9] Y. Pan, S. Lin, R. Xing et al., "Epigenetic upregulation of metallothionein 2A by diallyl trisulfide enhances chemosensitivity of human gastric cancer cells to docetaxel through attenuating NF- κ B activation," *Antioxidants and Redox Signaling*, vol. 24, no. 15, pp. 839–854, 2016.
- [10] Y. Pan, J. Huang, R. Xing et al., "Metallothionein 2A inhibits NF- κ B pathway activation and predicts clinical outcome segregated with TNM stage in gastric cancer patients following radical resection," *Journal of Translational Medicine*, vol. 11, no. 1, p. 173, 2013.
- [11] A. Sekovanić, J. Jurasović, and M. Piasek, "Metallothionein 2A gene polymorphisms in relation to diseases and trace element levels in humans," *Archives of Industrial Hygiene and Toxicology*, vol. 71, no. 1, pp. 27–47, 2020.
- [12] J. Wang, P. Huang, W. Zhao, W. Ren, L. Ai, and L. Wu, "Quantitative assessment of the association of polymorphisms in the metallothionein 2A gene with cancer risk," *Journal of International Medical Research*, vol. 48, no. 8, Article ID 030006052094793, 2020.
- [13] A. Krześlak, E. Forma, P. Józwiak et al., "Metallothionein 2A genetic polymorphisms and risk of ductal breast cancer," *Clinical and Experimental Medicine*, vol. 14, no. 1, pp. 107–113, 2014.
- [14] M. Shokrzadeh, A. Mohammadpour, N. Ghassemi-Barghi, V. Hoseini, S. Abediankenari, and Y. S. Tabari, "METALLOTHIONEIN-2A (RS1610216&RS28366003) gene polymorphisms and the risk of stomach adenocarcinoma," *Arquivos de Gastroenterologia*, vol. 56, no. 4, pp. 367–371, 2019.
- [15] E. Forma, A. Krzeslak, J. Wilkosz et al., "Metallothionein 2A genetic polymorphisms and risk of prostate cancer in a polish population," *Cancer Genetics*, vol. 205, no. 9, pp. 432–435, 2012.
- [16] Y. L. Tai, L. C. Chen, and T. L. Shen, "Emerging roles of focal adhesion kinase in cancer," *BioMed Research International*, vol. 2015, Article ID 690690, 13 pages, 2015.
- [17] L. J. Kornberg, "Focal adhesion kinase and its potential involvement in tumor invasion and metastasis," *Head & Neck*, vol. 20, no. 8, pp. 745–752, 1998.
- [18] V. M. Golubovskaya, F. A. Kweh, and W. G. Cance, "Focal adhesion kinase and cancer," *Histology & Histopathology*, vol. 24, no. 4, pp. 503–510, 2009.
- [19] T. Du, Y. Qu, J. Li et al., "Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway," *Molecular Cancer*, vol. 13, no. 1, p. 100, 2014.
- [20] J. H. Park, B. L. Lee, J. Yoon et al., "Focal adhesion kinase (FAK) gene amplification and its clinical implications in gastric cancer," *Human Pathology*, vol. 41, no. 12, pp. 1664–1673, 2010.
- [21] J. Du, L. Fu, J. Hao, X. Lin, and Q. Dong, "Rab11a is overexpressed in gastric cancer and regulates FAK/AKT signaling," *Journal of Oncology*, vol. 2020, Article ID 3494396, 13 pages, 2020.
- [22] Q. Luo, S. Zhang, D. Zhang, F. Yuan, X. Chen, and S. Yang, "Expression of ASAP1 and FAK in gastric cancer and its clinicopathological significance," *Oncology Letters*, vol. 20, no. 1, pp. 974–980, 2020.
- [23] T. Miyazaki, H. Kato, M. Nakajima et al., "FAK overexpression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma," *British Journal of Cancer*, vol. 89, no. 1, pp. 140–145, 2003.
- [24] J. Zhou, J. W. Roh, S. Bandyopadhyay et al., "Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma," *Gynecologic Oncology*, vol. 128, no. 2, pp. 344–348, 2013.
- [25] K. Ren, X. Lu, N. Yao et al., "Focal adhesion kinase overexpression and its impact on human osteosarcoma," *Oncotarget*, vol. 6, no. 31, pp. 31085–31103, 2015.
- [26] X. Tong, R. Tanino, R. Sun et al., "Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer," *Respiratory Research*, vol. 20, no. 1, p. 270, 2019.
- [27] F. Aboubakar Nana, M. Van Derputten, and S. Ocak, "Role of focal adhesion kinase in small-cell lung cancer and its potential as a therapeutic target," *Cancers*, vol. 11, no. 11, p. 1683, 2019.
- [28] J. M. Murphy, Y. A. R. Rodriguez, K. Jeong, E. E. Ahn, and S. S. Lim, "Targeting focal adhesion kinase in cancer cells and the tumor microenvironment," *Experimental and Molecular Medicine*, vol. 52, no. 6, pp. 877–886, 2020.
- [29] Q. Zhang, H. Wang, H. Wei, and D. Zhang, "Focal adhesion kinase (FAK) is associated with poor prognosis in urinary bladder carcinoma," *International Journal of Clinical and Experimental Pathology*, vol. 11, no. 2, pp. 831–838, 2018.
- [30] L. Hu, Y. T. Duan, J. F. Li et al., "Biglycan enhances gastric cancer invasion by activating FAK signaling pathway," *Oncotarget*, vol. 5, no. 7, pp. 1885–1896, 2014.
- [31] H. Yan, M. Guo, J. Zou et al., "Promotive effect of Talin-1 protein on gastric cancer progression through PTK2-PXN-VCL-E-Cadherin-CAPN2-MAPK1 signaling axis," *Journal of Clinical Laboratory Analysis*, vol. 34, no. 12, Article ID e23555, 2020.
- [32] L. Yang, L. G. Kuang, H. C. Zheng et al., "PTEN encoding product: a marker for tumorigenesis and progression of

- gastric carcinoma," *World Journal of Gastroenterology*, vol. 9, no. 1, pp. 35–39, 2003.
- [33] I. A. Charitos, D. D'Agostino, S. Topi, and L. Bottalico, "40 years of *Helicobacter pylori*: a revolution in biomedical thought," *Gastroenterology Insights*, vol. 12, no. 2, pp. 111–135, 2021.
- [34] K. Dadashzadeh, M. P. Peppelenbosch, and A. I. Adamu, "*Helicobacter pylori* pathogenicity factors related to gastric cancer," *Canadian Journal of Gastroenterology and Hepatology*, vol. 2017, Article ID 7942489, 6 pages, 2017.
- [35] N. Tegtmeyer, S. Wessler, and S. Backert, "Role of the *cag* pathogenicity island encoded type IV secretion system in *Helicobacter pylori* pathogenesis," *FEBS Journal*, vol. 278, no. 8, pp. 1190–1202, 2011.
- [36] J. Y. Park, D. Forman, L. A. Waskito, Y. Yamaoka, and J. E. Crabtree, "Epidemiology of *Helicobacter pylori* and CagA-positive infections and global variations in gastric cancer," *Toxins*, vol. 10, no. 4, p. 163, 2018.
- [37] G. Suarez, J. Romero-Gallo, J. C. Sierra et al., "Genetic manipulation of *Helicobacter pylori* virulence function by host carcinogenic phenotypes," *Cancer Research*, vol. 77, no. 9, pp. 2401–2412, 2017.
- [38] R. A. Aras, W. Fischer, G. I. Perez-Perez et al., "Plasticity of repetitive DNA sequences within a bacterial (type IV) secretion system component," *Journal of Experimental Medicine*, vol. 198, no. 9, pp. 1349–1360, 2003.
- [39] R. M. Barrozo, L. M. Hansen, A. M. Lam et al., "CagY is an immune-sensitive regulator of the *Helicobacter pylori* type IV secretion system," *Gastroenterology*, vol. 151, no. 6, pp. 1164–1175, 2016.
- [40] E. M. Johnson, J. A. Gaddy, and T. L. Cover, "Alterations in *Helicobacter pylori* triggered by contact with gastric epithelial cells," *Frontiers in Cellular and Infection Microbiology*, vol. 2, p. 17, 2012.
- [41] J. B. Du Prel, B. Rohrig, G. Hommel, and M. Blettner, "Choosing statistical tests: part 12 of a series on evaluation of scientific publications," *Deutsches Arzteblatt International*, vol. 107, no. 19, pp. 343–348, 2010.
- [42] B. K. Nayak and A. Hazra, "How to choose the right statistical test?" *Indian Journal of Ophthalmology*, vol. 59, no. 2, pp. 85–86, 2011.
- [43] A. Mentis, P. Lehours, and F. Megraud, "Epidemiology and diagnosis of *Helicobacter pylori* infection," *Helicobacter*, vol. 20, pp. 1–7, 2015.
- [44] M. Barari, P. Sharifi, V. Yousefinejad et al., "Effect of curcumin on eradication of *Helicobacter pylori* infection," *SJKU*, vol. 25, no. 6, pp. 57–67, 2021.
- [45] J. H. Scheffe, K. E. Lehmann, I. R. Buschmann, T. Unger, and H. Funke-Kaiser, "Quantitative real-time RT-PCR data analysis: current concepts and the novel "gene expression's CT difference" formula," *Journal of Molecular Medicine (Berlin)*, vol. 84, no. 11, pp. 901–910, 2006.
- [46] J. C. Atherton, P. Cao, R. M. Peek, M. K. Tummuru, M. J. Blaser, and T. L. Cover, "Mosaicism in vacuolating cytotoxin alleles of *Helicobacter pylori*," *Journal of Biological Chemistry*, vol. 270, no. 30, pp. 17771–17777, 1995.
- [47] L. Van Doorn, C. Figueiredo, R. Sanna et al., "Clinical relevance of the *cagA*, *vacA*, and *iceA* status of *Helicobacter pylori*," *Gastroenterology*, vol. 115, no. 1, pp. 58–66, 1998.
- [48] L. A. Sicinschi, P. Correa, L. E. Bravo et al., "Non-invasive genotyping of *Helicobacter pylori* *cagA*, *vacA*, and *hopQ* from asymptomatic children," *Helicobacter*, vol. 17, no. 2, pp. 96–106, 2012.
- [49] H. Okamoto, K. Yasui, C. Zhao, S. Aii, and J. Inazawa, "PTK2 and EIF3S3 genes may be amplification targets at 8q23–q24 and are associated with large hepatocellular carcinomas," *Hepatology*, vol. 38, no. 5, pp. 1242–1249, 2003.
- [50] T. P. Liu, Y. H. Hong, K. Y. Tung, and P. M. Yang, "In silico and experimental analyses predict the therapeutic value of an EZH2 inhibitor GSK343 against hepatocellular carcinoma through the induction of metallothionein genes," *Oncoscience*, vol. 3, no. 1, pp. 9–20, 2016.
- [51] M. Kim, M. Ogawa, Y. Fujita et al., "Bacteria hijack integrin-linked kinase to stabilize focal adhesions and block cell detachment," *Nature*, vol. 459, no. 7246, pp. 578–582, 2009.